You are here

Share:

Deuterium Magnetic Resonance Imaging (dMRI) for In Vivo Visualization of Rapidly-Dividing Cells

Summary
The National Cancer Institute seeks licensees for a method for in vivo visualization of rapidly-dividing cells and dynamic measurement of cellular kinetics using Deuterium Magnetic Resonance Imaging (dMRI).
NIH Reference Number
E-188-2016
Product Type
Keywords
  • MRI, deuterium, dMRI, graft-versus-host disease, GVHD, imaging
Collaboration Opportunity
This invention is available for licensing.
Contact
Description of Technology

Chronic graft-versus-host disease (cGVHD) is a prevalent and highly lethal condition affecting stem cell transplant recipients. The need for biopsy often delays identification and treatment of cGVHD and other diseases characterized by the presence of rapidly dividing cells, such as cancer. Unfortunately, biopsies are a painful, invasive and slow procedure, which cause discomfort to patients and do not yield rapid results. Because rapid, reliable, and early detection of cGVHD, and other diseases or conditions characterized by the presence of rapidly dividing cells, can improve the long-term prognosis of the patient, there is a need for faster and less invasive diagnostic methods.

Researchers at the National Cancer Institute’s Experimental Transplantation and Immunology Branch (NCI ETIB) have developed an improved method for detection of diseases characterized by the presence of rapidly-dividing cells, as validated in in vitro studies. This method involves the use of deuterated water as a label for dynamic measurement of in vivo cellular kinetics. Importantly, this imaging method is non-invasive, and does not use any radioactive isotopes. The use of this labeling method in vivo, in conjunction with MRI modalities such as deuterium MRI [dMRI] or 17O MRI, could illuminate disease-specific pathophysiology, identify targets for therapeutic interventions, and facilitate diagnosis of conditions characterized by rapidly dividing cells.

The National Cancer Institute seeks licensees for a method for in vivo visualization of rapidly-dividing cells and dynamic measurement of cellular kinetics using Deuterium Magnetic Resonance Imaging (dMRI). If you are interested in more details, please Email TTC.  

Potential Commercial Applications
  • Non-invasive diagnostic, non-radioactive labeling-imaging approach for many cell types, including neoplastic cells.
Competitive Advantages
  • Less invasive alternative to current diagnostic procedures, such as biopsies: decreases patient discomfort.
  • Faster detection method can improve patient responses to treatment and survival rates
Development Stage
Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number 62/414,554, Filed 16 Oct 2016
  • Foreign Filed: US - Patent Application PCT/US2017/058856, Filed 27 Oct 2017
  • U.S. Patent Filed: U.S. Patent Application Number PCT/US2017/058856 , Filed 27 Oct 2017
Therapeutic Area
Updated
Friday, February 2, 2018